Key facts
- It has raised $2.1M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, Shinhan Venture Investment, Lotte Ventures, NongHyup Bank — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Biocom
- ·The full record, as it builds
Funding rounds
No funding rounds for Biocom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biocom
Operator of an innovative bio-healthcare company intended to provide non-face-to-face healthcare services. The company conducts deep research into people, food, plants, animals, and the environment to manage practices that are helpful to the world, enabling people who feel anti-health symptoms to become healthier and excellent.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 43
- Website
- biocom.kr/
- Ownership
- Privately Held (backing)
Biocom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biocom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biocom in its N-PORT filings yet. We sweep new filings monthly.